71 related articles for article (PubMed ID: 12085221)
21. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Fauser AA; Duclos B; Chemaissani A; Del Favero A; Cognetti F; Diaz-Rubio E; Cortes-Funes H; Conte PF; Dressler H
Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
[TBL] [Abstract][Full Text] [Related]
22. BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.
Newberry NR; Watkins CJ; Sprosen TS; Blackburn TP; Grahame-Smith DG; Leslie RA
Neuropharmacology; 1993 Aug; 32(8):729-35. PubMed ID: 8413836
[TBL] [Abstract][Full Text] [Related]
23. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group.
Smith IE
J Cancer Res Clin Oncol; 1993; 119(6):350-4. PubMed ID: 8383688
[TBL] [Abstract][Full Text] [Related]
24. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group.
Soukop M
Support Care Cancer; 1994 May; 2(3):177-83. PubMed ID: 8032704
[TBL] [Abstract][Full Text] [Related]
25. Ondansetron clinical pharmacokinetics.
Roila F; Del Favero A
Clin Pharmacokinet; 1995 Aug; 29(2):95-109. PubMed ID: 7586904
[TBL] [Abstract][Full Text] [Related]
26. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Carmichael J; Cantwell BM; Edwards CM; Zussman BD; Thompson S; Rapeport WG; Harris AL
Cancer Chemother Pharmacol; 1989; 24(1):45-9. PubMed ID: 2541937
[TBL] [Abstract][Full Text] [Related]
27. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist.
Upward JW; Arnold BD; Link C; Pierce DM; Allen A; Tasker TC
Eur J Cancer; 1990; 26 Suppl 1():S12-5. PubMed ID: 2169778
[TBL] [Abstract][Full Text] [Related]
28. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
[TBL] [Abstract][Full Text] [Related]
29. Phase I and other dose-ranging studies of ondansetron.
Grunberg SM
Semin Oncol; 1992 Aug; 19(4 Suppl 10):16-22. PubMed ID: 1387246
[TBL] [Abstract][Full Text] [Related]
30. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
Blower P; Aapro M
Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
[No Abstract] [Full Text] [Related]
31. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
32. Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
Lindley C; Blower P
Am J Health Syst Pharm; 2000 Sep; 57(18):1685-97. PubMed ID: 11006796
[TBL] [Abstract][Full Text] [Related]
33. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
34. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
35. [Serotonin and anticancer drug-induced emesis].
Minami M; Endo T; Hamaue N; Hirafuji M
Yakugaku Zasshi; 2004 Aug; 124(8):491-507. PubMed ID: 15297719
[TBL] [Abstract][Full Text] [Related]
36. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
37. Are there differences among the serotonin antagonists?
Tonato M; Roila F; Del Favero A
Support Care Cancer; 1994 Sep; 2(5):293-6. PubMed ID: 8000725
[TBL] [Abstract][Full Text] [Related]
38. Review of experience with ondansetron and granisetron.
Aapro MS
Ann Oncol; 1993; 4 Suppl 3():9-14. PubMed ID: 8395875
[TBL] [Abstract][Full Text] [Related]
39. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
Rabasseda X
Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
[TBL] [Abstract][Full Text] [Related]
40. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
Tan M
Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
